News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Epizyme (EPZM) to Present at Upcoming Conferences in July


6/27/2013 6:46:14 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., June 27, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming conferences.

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing).

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.

SOURCE Epizyme, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
Epizyme
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES